-+ 0.00%
-+ 0.00%
-+ 0.00%

Seres Therapeutics Appoints Richard N. Kender As Executive Chair And Interim CEO

Benzinga·03/02/2026 21:13:40
Listen to the news

Seres Therapeutics, Inc. (NASDAQ:MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced the appointment of Richard N. Kender as Executive Chair and Interim Chief Executive Officer. Mr. Kender, who brings over 35 years of biopharma executive experience, including as Senior Vice President, Business Development and Corporate Licensing at Merck & Co., has served on the Seres Board of Directors since September 2014. Mr. DesRosier and Ms. Thorell, previously co-CEOs of Seres, will continue to serve as Chief Legal Officer and Chief Financial Officer, respectively.